Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,65 USD | -7,02% | +2,71% | +97,76% |
20/03 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
20/03 | Trevi Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023 | CI |
Vakgebied
Aantal werknemers: 25
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 01-03-11 |
Thomas Sciascia
FOU | Founder | 70 | 01-01-11 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 09-08-21 |
Danine Summers
CTO | Chief Tech/Sci/R&D Officer | - | 09-08-21 |
David J. Clark
CTO | Chief Tech/Sci/R&D Officer | 59 | 14-11-22 |
Katie McManus
IRC | Investor Relations Contact | - | - |
Katherine Takaki
LAW | General Counsel | - | - |
Farrell Simon
PRN | Corporate Officer/Principal | 42 | 01-02-23 |
Comptroller/Controller/Auditor | - | 12-04-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 10-10-18 |
James Cassella
BRD | Director/Board Member | 69 | 13-02-20 |
Jennifer Good
FOU | Founder | 59 | 01-03-11 |
Director/Board Member | 60 | 29-06-20 | |
Director/Board Member | 64 | 01-07-17 | |
Director/Board Member | 59 | 01-02-17 | |
David Meeker
CHM | Chairman | 69 | 01-07-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 68 960 167 | 68 077 718 ( 98,72 %) | 0 | 98,72 % |
Bedrijfsgegevens
Trevi Therapeutics, Inc.
195 Church Street 14th floor
06510, New Haven
+
http://www.trevitherapeutics.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+97,76% | 183 mln. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,75% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,96% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |
- Beurs
- Aandelen
- Koers TRVI
- Onderneming Trevi Therapeutics, Inc.